Amalgamated Financial’s BridgeBio Pharma BBIO Stock Holding History

Amalgamated Financial’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$160K	Buy	+15,794	New	+$162K	﹤0.01%	1982

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Amalgamated Financial's BBIO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in BridgeBio Pharma (BBIO) in Q1 2022: 15,794 shares worth $160K. The stake represents ﹤0.01% of the portfolio and ranks #1982 among its holdings.

178 funds tracked by Wall St. Rank hold BBIO as of Q1 2022.

Amalgamated Financial held 15,794 shares of BridgeBio Pharma worth $160K as of Q1 2022.
BridgeBio Pharma was a new Amalgamated Financial position in Q1 2022.
BridgeBio Pharma made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1982 holding.
178 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.